Maple Capital Management Inc. Sells 3,793 Shares of Danaher Co. (NYSE:DHR)

Maple Capital Management Inc. cut its position in shares of Danaher Co. (NYSE:DHR) by 16.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 19,712 shares of the conglomerate’s stock after selling 3,793 shares during the period. Maple Capital Management Inc.’s holdings in Danaher were worth $5,480,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. AdvisorNet Financial Inc grew its position in Danaher by 11.3% during the 1st quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock worth $189,000 after acquiring an additional 77 shares during the last quarter. CGN Advisors LLC bought a new stake in shares of Danaher in the 1st quarter worth approximately $205,000. Austin Private Wealth LLC grew its position in shares of Danaher by 3.0% in the 1st quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock worth $383,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co bought a new stake in shares of Danaher in the 1st quarter worth approximately $119,000. Finally, Dynamic Advisor Solutions LLC grew its position in shares of Danaher by 8.3% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 7,744 shares of the conglomerate’s stock worth $1,934,000 after buying an additional 591 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last quarter. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $265.00 on Tuesday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a market capitalization of $196.28 billion, a PE ratio of 46.15, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The firm’s 50 day moving average price is $270.82 and its 200-day moving average price is $260.34. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the business earned $2.05 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year. Equities research analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent analyst reports. Evercore ISI lifted their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. The Goldman Sachs Group raised their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus raised their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird raised their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.